Back to all articles
•Technology

Aloe Blacc Transitions from Music to Biotech Innovation

View original source

In a revealing episode of TechCrunch's Equity podcast, Grammy-nominated artist Aloe Blacc shares his unexpected journey from music to biotech innovation. Key discussion points include:

  • Blacc's personal battle with COVID, despite being vaccinated and boosted, which motivated him to engage in biotech research.
  • The challenges he faced regarding commercialization in biotech, such as the regulatory needs for a commercialization plan and the limitations of philanthropy in advancing scientific trials.
  • His efforts in developing a cancer drug platform focused on pancreatic cancer, a condition with a notoriously high mortality rate.
  • Insight into his strategic decision to delay external funding until peer-reviewed publications validate his work.
  • The conversation continues with discussions on AI's impact on biotech and music industries. Blacc predicts record labels will drive AI-generated music economics over artists or tech firms.
  • He also explores how a University of Houston's discovery platform could significantly reduce drug development timelines and discusses his continued belief in traditional musical techniques despite AI advancements.
  • Podcast availability mentioned on platforms like Apple Podcasts, Spotify, and their own website, alongside efforts to reach out on platforms such as Twitter and Threads.